Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SCYX
SELLSCYNEXIS, Inc. · Healthcare · United States · $58M · Avg Vol: $313K/d
COMPANY DESCRIPTION
SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing novel therapies to overcome and prevent difficult-to-treat infections. The company's primary asset is ibrexafungerp, a first-in-class oral antifungal agent that serves as a strong competitive moat against traditional, resistant fungal strains. It operates as a specialty pharmaceutical player targeting the high-unmet-need anti-infective market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.1M | 140.1M | 3.7M | 20.6M | 59.4% | 20.3M | 1.2M | 6.7M | -43.1% |
| EPS | -4.84 | 5.25 | -1.68 | -1.36 | — | -3.47 | -4.08 | -2.52 | — |
| Shares | 9.9M | 9.9M | 9.9M | 5.4M | -45.2% | — | — | — | — |
| Debt | 48.6M | 15.1M | 16.3M | 2.2M | -64.5% | 2.1M | — | — | — |
| Equity | 3.2M | 73.0M | 55.1M | 49.4M | 148.1% | — | — | — | — |
| Op CF | -79.9M | 60.2M | -24.0M | -5.3M | — | -5.9M | — | — | — |
| Inv CF | -27.4M | -34.9M | 6.2M | 24.3M | — | — | — | — | — |
| Fin CF | 48.6M | -36.7M | -0.1M | -14.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SCYX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SCYX | SCYNEXIS, Inc.(you) | $58M | 33 | SELL |
| JUSH.CN | Jushi Holdings Inc. | $83M | 31 | SELL |
| TLPH | Talphera, Inc. | $70M | 22 | SELL |
| GRIN.CN | Grown Rogue International Inc. | $109M | 39 | HOLD |
| CWEB.TO | Charlotte's Web Holdings, Inc. | $67M | 16 | STRONG SELL |
| DERM | Journey Medical Corporation | $170M | 24 | SELL |
| CTOR | Citius Oncology, Inc. | $52M | 2 | STRONG SELL |
| TKNO | Alpha Teknova, Inc. | $266M | 37 | HOLD |
| AKBA | Akebia Therapeutics, Inc. | $327M | 30 | SELL |
| ORGO | Organogenesis Holdings Inc. | $308M | 38 | HOLD |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%